✦ LIBER ✦

2.234 RISK FACTORS FOR LEVODOPA-RELATED DYSKINESIAS IN PARKINSON'S DISEASE

✍ Scribed by H. Zhang; S. Chen; N. Ren; Y. Liu

Book ID: 117754927
Publisher: Elsevier Science
Year: 2012
Tongue: English
Weight: 54 KB
Volume: 18
Category: Article
ISSN: 1353-8020
DOI: 10.1016/s1353-8020(11)70558-2

No coin nor oath required. For personal study only.

📜 SIMILAR VOLUMES

Risk factors for levodopa-induced dyskin

Risk factors for levodopa-induced dyskinesias in Parkinson’s disease

✍ Grandas, F.; Galiano, Maria Luisa; Tabernero, Cesar 📂 Article 📅 1999 🏛 Springer 🌐 English ⚖ 91 KB

Olanzapine reduces levodopa-related dysk

Olanzapine reduces levodopa-related dyskinesias in patients with Parkinson's disease

✍ M. Canesi; A. Antonini; A. Colzi; D. Bravi; O. Pezzoli 📂 Article 📅 1999 🏛 Elsevier Science 🌐 English ⚖ 139 KB

Classifying risk factors for dyskinesia

Classifying risk factors for dyskinesia in Parkinson’s disease

✍ J.C. Sharma; C.G. Bachmann; G. Linazasoro 📂 Article 📅 2010 🏛 Elsevier Science 🌐 English ⚖ 228 KB

Risk factors and predictors of levodopa-

Risk factors and predictors of levodopa-induced dyskinesia among multiethnic Malaysians with Parkinson's disease

✍ Hashim, H. Z.; Norlinah, M. I.; Nafisah, W. Y.; Tan, H. J.; Raymond, A. A.; Tami 📂 Article 📅 2013 🏛 Informa plc 🌐 English ⚖ 97 KB

Levetiracetam for the management of levo

Levetiracetam for the management of levodopa-induced dyskinesias in Parkinson's disease

✍ P. Stathis; S. Konitsiotis; G. Tagaris; D. Peterson; on Behalf of VALID-PD Study 📂 Article 📅 2010 🏛 John Wiley and Sons 🌐 English ⚖ 265 KB

Repetitive transcranial magnetic stimula

Repetitive transcranial magnetic stimulation for levodopa-induced dyskinesias in Parkinson's disease

✍ Saša R. Filipović; John C. Rothwell; Bart P. van de Warrenburg; Kailash Bhatia 📂 Article 📅 2009 🏛 John Wiley and Sons 🌐 English ⚖ 163 KB

## Abstract In a placebo‐controlled, single‐blinded, crossover study, we assessed the effect of “real” repetitive transcranial magnetic stimulation (rTMS) versus “sham” rTMS (placebo) on peak dose dyskinesias in patients with Parkinson's disease (PD). Ten patients with PD and prominent dyskinesias